IMMUNITYBIO INC (IBRX) Earnings History & Surprises
NASDAQ:IBRX • US45256X1037
8.96 USD
-0.04 (-0.44%)
At close: Mar 5, 2026
8.9535 USD
-0.01 (-0.07%)
After Hours: 3/5/2026, 8:00:02 PM
Past quarterly earnings results for IMMUNITYBIO INC (IBRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$0.08
Revenue Estimate44.045M
Last Reported
Release DateFeb 23, 2026
PeriodQ4 / 2025
EPS Reported-$0.06
EPS Surprise 37.42%
Revenue Surprise 1.39%
Beat Rate
63%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.06 | -0.10 | 37.42% | 33.33% | 38.285M | 37.76M | 1.39% | 406.95% |
| Q3 2025 | -0.07 | -0.11 | 36.46% | 41.67% | 32.061M | 32.518M | -1.41% | 425.07% |
| Q2 2025 | -0.10 | -0.11 | 10.87% | 50.00% | 26.425M | 23.223M | 13.79% | 2,423.88% |
| Q1 2025 | -0.15 | -0.13 | -14.89% | 25.00% | 16.517M | 16.335M | 1.11% | 41,192.50% |
| Q4 2024 | -0.09 | -0.20 | 55.88% | 74.29% | 7.552M | 7.973M | -5.28% | 5,333.09% |
| Q3 2024 | -0.12 | -0.18 | 34.64% | 36.84% | 6.106M | 2.985M | 104.56% | 7,346.34% |
| Q2 2024 | -0.20 | -0.17 | -15.34% | 37.50% | 1.047M | 2.57M | -59.26% | 2,453.66% |
| Q1 2024 | -0.20 | -0.16 | -22.55% | 25.93% | 40K | 25.5K | 56.86% | -88.89% |
| Q4 2023 | -0.35 | -0.18 | -90.63% | -29.63% | 139K | 25.5K | 445.10% | 98.57% |
| Q3 2023 | -0.19 | -0.26 | 26.95% | 32.14% | 82K | 25.5K | 221.57% | -31.67% |
| Q2 2023 | -0.32 | -0.24 | -33.50% | -33.33% | 41K | 25.5K | 60.78% | 2.50% |
| Q1 2023 | -0.27 | -0.28 | 1.96% | -3.85% | 360K | 25.5K | 1,311.76% | 3,500.00% |
| Q4 2022 | -0.27 | -0.22 | -20.32% | -17.39% | 70K | 25.5K | 174.51% | -82.05% |
| Q3 2022 | -0.28 | -0.23 | -19.35% | -27.27% | 120K | 25.5K | 370.59% | 71.43% |
| Q2 2022 | -0.24 | -0.24 | 1.96% | -4.35% | 40K | 25.5K | 56.86% | -88.24% |
| Q1 2022 | -0.26 | -0.22 | -15.86% | -23.81% | 10K | 25.5K | -60.78% | -92.86% |
| Q4 2021 | -0.23 | -0.21 | -7.38% | 23.33% | 390K | 25.5K | 1,429.41% | 360.00% |
| Q3 2021 | -0.22 | -0.20 | -7.84% | -10.00% | 70K | 25.5K | 174.51% | -53.33% |
| Q2 2021 | -0.23 | -0.12 | -87.91% | -15.00% | 340K | 25.5K | 1,233.33% | -22.73% |
| Q1 2021 | -0.21 | -0.42 | 49.78% | -10.53% | 140K | 25.5K | 449.02% | -17.65% |
| Q4 2020 | -0.30 | -0.18 | -63.40% | - | -150K | 15.3K | -1,080.39% | - |
| Q3 2020 | -0.20 | -0.18 | -8.93% | - | 150K | 7.65K | 1,860.78% | - |
| Q2 2020 | -0.20 | -0.19 | -3.20% | - | 440K | 7.65K | 5,651.63% | - |
| Q1 2020 | -0.19 | -0.17 | -9.57% | - | 170K | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
17.47%
Max EPS beat (4)
37.42%
Min EPS beat (4)
-14.89%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
3.72%
Max Revenue beat (4)
13.79%
Min Revenue beat (4)
-1.41%
Analysis
In the last 4 quarters, IBRX has beaten EPS estimates in 3 out of 4 releases
IBRX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, IBRX has beaten the EPS estimates by 17.5% on average.
In the last 4 quarters, IBRX has beaten the revenue estimates by 3.7% on average.
IMMUNITYBIO INC / IBRX Earnings FAQ
Can you provide the last earnings date for IMMUNITYBIO INC?
IMMUNITYBIO INC (IBRX) last reported earnings on 2/23/2026.
Did IMMUNITYBIO INC (IBRX) beat earnings estimates last quarter?
IMMUNITYBIO INC (IBRX) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does IBRX stock beat earnings estimates?
In the last 4 quarters, IMMUNITYBIO INC (IBRX) has beaten EPS estimates in 3 out of 4 releases.